- Home
- IQ vs GLPG Comparison
IQ vs GLPG Comparison
Compare IQ & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQ | GLPG |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IQ | GLPG |
|---|---|---|
| Price | $1.93 | $33.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | $2.91 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 9.3M | 117.7K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,808,085,043.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $2.47 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $1.50 | $22.36 |
| 52 Week High | $2.84 | $37.78 |
Technical Indicators
Market Signals| Indicator | IQ | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.22 | 46.72 |
| Support Level | $1.88 | $33.53 |
| Resistance Level | $2.19 | $34.88 |
| Average True Range (ATR) | 0.08 | 0.73 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 14.57 | 41.81 |
Price Performance
Historical ComparisonAbout IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.